Combined treatment of multiple sclerosis

Details Combined treatment of multiple sclerosis Combined treatment of multiple sclerosis

1997-09-24

2000-05-09

Travers, Russell

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514376, A01N 4376, A01N 4336

Patent

active

060605014

ABSTRACT:
A pharmaceutically composition for treating MS comprising an effective amount of a combination of a PDE IV inhibitor and an anti-inflammatory and immunomodulatory drug in a pharmaceutically acceptable carrier.

REFERENCES:
patent: 4153713 (1979-05-01), Huth et al.
patent: 4943573 (1990-07-01), Meanwell et al.
patent: 5227369 (1993-07-01), Rosen et al.
patent: 5420154 (1995-05-01), Christensen, IV et al.
patent: 5541219 (1996-07-01), Fenton et al.
"Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes", C.D. Nicholson et al., TiPS, vol. 12, Jan. 1991.
"Inhibition of Eosinophil Oxygen Radical Production by Type IV--But Not Type III--Selective cAMP Phosphodiesterase Inhibitors", G. Dent et al., Br. J. Pharm., vol. 22 (163P), 1990.
"Pentoxifylline inhibits experimental allergic encephalomyelitis", S. Nataf et al., Acta Neurol. Scand., vol. 88, 1993, pp. 97-99.
"Regulation of Tumor Necrosis Factor Expression in Macrophage-like Cell Line by Lipopolysaccharide and cyclic AMP", S.M. Taffet et al., Cellular Immunology, vol. 120, 1989, pp. 291-300.
"The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle", M.L. Reeves et al., Biochem J., vol. 241, 1987, pp. 535-541.
"Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats", O. Rott et al., Eur. J. Immunol., vol. 23, 1993, pp. 1745-1751.
"The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages", F.U. Schade and C. Schudt, Eur. J. Pharma., vol. 230, 1993, pp. 9-14.
"Multiple Sclerosis and Allied Demyelinative Diseases", Principles of Neurology, 1993, pp. 777-791.
Abstract, "Tumor-necrosis factor-directed therapy of autoimmune . . . ", Sommer et al., J. Neurol. vol. 54(1-2), 1994, p. 198.
Spengler et al., "Dynamics of Cyclic AMP- and Prostaglandin . . . ," Infection and Immunity, 57(9):2837-2841, Sep. 1989.
Lloyd J. Old, "Tumor necrosis factor: Another chapter in the long . . . ," Nature, vol. 330, pp. 602-603, Dec. 17, 1987.
Millar et al., "Tumour Necrosis Factor in Bronchopulmonary . . . ," Lancet, vol. II for 1989, pp. 712-714, Sep. 23, 1989.
Dezube et al., "Pentoxifylline and wellbeing in patients with cancer," Lancet, 335(8690):662, Mar. 17, 1990.
Frolich et al., "Is the Elevation of Cyclic . . . ," J. Invest. Dermat., 90(2):240, 1988.
Marivet et al., "Inhibition of Cyclic Adenosine-3',5'-monophosphate . . . ," J. Med. Chem., 32:1450-1457, 1989.
"Pentoxifylline inhibits experimental allergic encephalomyelitis", S. Nataf et al., Acta Neurol. Scand., vol. 88, 1993, pp. 97-99.
"Differential regulation of TNF-.alpha. and IL-1.beta. production from endotoxin stimulated . . . ", Molnar-Kimber et al., Mediators of Inflammation.
Sharief et al., "Association Between Tumor Necrosis Factor-alpha . . . ," New England J. of Med., 325(7) :467-472, Aug. 15, 1991.
Kirby et al., "Prostacyclin Increases Cyclic-Nucleotide . . . ," The Lancet, 2(8192):453-454, Aug. 30, 1980.
Renz et al., "Release of Tumor Necrosis Factor-.alpha. From Macrophages . . . ," J. of Immunology, pp. 2388-2393, Oct. 1, 1988.
Strieter et al., "Cellular and Molecular Regulation of Tumor . . . ," Biochem. and Biophys. Research Comm., 155(3):1230-1236, Sep. 30, 1988.
"Demyelinating Diseases", Cecil Textbook of Medicine, Wyngaarden et al., eds., 19th ed., 1992, pp. 2199-2200.
Lowe et al, J. Med. Chm 1991 vol. 34, p624-28.
Merch Manual, 14.sup.th ed, 1982, p 1354-56.

Affiliated with

Also associated with

Rating

Combined treatment of multiple sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combined treatment of multiple sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined treatment of multiple sclerosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1065575